CBT for Adolescents With Excessive Worry (BiPOro)

December 20, 2017 updated by: Eva Serlachius, Karolinska Institutet

Cognitive Behavioral Therapy for Adolescents With Excessive Worry - a Case Series

This case series aims to test the feasibility and acceptability of streamlined cognitive behavioral therapy (CBT) for adolescents with excessive worry. The treatment protocol focuses on reducing intolerance of uncertainty and the hypothesis is that this will help reduce worry.

Study Overview

Status

Completed

Conditions

Detailed Description

This pilot study aims to test a new form of Cognitive Behavioral Therapy for adolescents with excessive worry. The investigators will include 12 participants with excessive worry and test the treatment which focuses on reducing intolerance of uncertainty (IU) in order to reduce worry.

Participants will be randomized to either one, two or three weeks of weekly baseline measurements prior to starting treatment, and will thus work as their on controls in this case series design.

Primary outcome measures will be collected at 12 weeks after treatment start. Participants will be followed up at three months after treatment.

Study Type

Interventional

Enrollment (Actual)

12

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Stockholm, Sweden, 171 77
        • Karolinska Institutet

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

13 years to 17 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • A score on PSWQ-C of at least 22
  • Age between 13 and 17 years
  • Ability to read and write in Swedish
  • A parent or caregiver that is able to co-participate in the treatment
  • Participants on psychotropic medication must have been on a stable dose for the last 6 weeks prior to baseline assessment

Exclusion Criteria:

  • Diagnosis of autism spectrum disorder, psychosis, bipolar disorder or severe eating disorder
  • Present risk of suicide
  • Ongoing substance dependence
  • Occurrence of domestic violence
  • Completed CBT for any anxiety disorder within the last 6 months (defined as at least 5 sessions of CBT including in vivo exposure sessions)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Cognitive Behavioral Therapy
All participants will receive cognitive behavioral therapy for excessive worry. Focus in treatment will be on reducing participants' intolerance uncertainty through in vivo and imaginary exposure to uncertainty inducing situations and thoughts. Treatment will also contain psycho education about anxiety and worry, as well as planning for maintenance of treatment gains. Parents of the participants will receive support and education about worry through an internet-delivered program.
CBT focused on reducing intolerance of uncertainty
Other Names:
  • CBT

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Penn State Worry Questionnaire for Children (PSWQ-C)
Time Frame: At 12 weeks after treatment starts
Child and parent version
At 12 weeks after treatment starts

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)
Time Frame: Baseline, 12 weeks after start of treatment and three month after treatment has ended.
Diagnostic interview
Baseline, 12 weeks after start of treatment and three month after treatment has ended.
Clinical Global Impression - Severity (CGI-S)
Time Frame: Baseline, 12 weeks after start of treatment and three month after treatment has ended.
Clinician rated severity of symptoms
Baseline, 12 weeks after start of treatment and three month after treatment has ended.
Clinical Global Impression - Improvement (CGI-I)
Time Frame: At 12 weeks after start of treatment and three month after treatment has ended.
Clinician rated improvement after treatment
At 12 weeks after start of treatment and three month after treatment has ended.
Children's Global Assessment Scale (CGAS)
Time Frame: Baseline, 12 weeks after start of treatment and three month after treatment has ended.
Clinician rated global functioning
Baseline, 12 weeks after start of treatment and three month after treatment has ended.
Brief Intolerance of Uncertainty Scale (Brief IUS)
Time Frame: Baseline, weekly during treatment, 12 weeks after treatment starts, and three months after treatment has ended
Self rated tolerance to treatment
Baseline, weekly during treatment, 12 weeks after treatment starts, and three months after treatment has ended
Brief Cognitive Avoidance Questionnaire (Brief CAQ)
Time Frame: Baseline, weekly during treatment, 12 weeks after treatment starts, and three months after treatment has ended
Self rated cognitive avoidance
Baseline, weekly during treatment, 12 weeks after treatment starts, and three months after treatment has ended
Brief Why Worry-II (Brief WW2)
Time Frame: Baseline, weekly during treatment, 12 weeks after treatment starts, and three months after treatment has ended
Self rated positive assumptions of worry
Baseline, weekly during treatment, 12 weeks after treatment starts, and three months after treatment has ended
Negative Problem Orientation Questionnaire (NPOQ)
Time Frame: Baseline, weekly during treatment, 12 weeks after treatment starts, and three months after treatment has ended
Self rated negative problem orientation
Baseline, weekly during treatment, 12 weeks after treatment starts, and three months after treatment has ended
Revised Children´s Anxiety and Depression Scale (RCADS-C)
Time Frame: Baseline, 12 weeks after start of treatment and three month after treatment has ended.
Child and parent version.
Baseline, 12 weeks after start of treatment and three month after treatment has ended.
Education, Work and Social Adjustment Scale (EWSAS)
Time Frame: Baseline, 12 weeks after start of treatment and three month after treatment has ended.
Child and parent version.
Baseline, 12 weeks after start of treatment and three month after treatment has ended.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2016

Primary Completion (Actual)

June 1, 2017

Study Completion (Actual)

October 1, 2017

Study Registration Dates

First Submitted

November 13, 2016

First Submitted That Met QC Criteria

November 28, 2016

First Posted (Estimate)

December 1, 2016

Study Record Updates

Last Update Posted (Actual)

December 22, 2017

Last Update Submitted That Met QC Criteria

December 20, 2017

Last Verified

December 1, 2017

More Information

Terms related to this study

Other Study ID Numbers

  • EPN DNR 2016/1408-31/5

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Excessive Worry

Clinical Trials on Cognitive behavioral therapy

3
Subscribe